Segment Information (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

Segment Reporting [Abstract]

Schedule of financial information by segment

	Three Months Ended March 31, 2021
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net sales	$	—		$	1,264	$	1,396		$	—			$	2,660
Gross profit		—			540		878			—				1,418
Direct expenses		16,287			252		2,014			6,063				24,616
Segment contribution		(16,287	)		288		(1,136	)		(6,063	)			(23,198	)
Indirect expenses										21,197		(a)	$	21,197
Loss from operations														(44,395	)
(a) Components of other
Change in fair value of contingent consideration liability										20,656
Amortization										541
Total other									$	21,197

	Three Months Ended March 31, 2020
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net sales	$	—		$	1,415	$	2,793		$	—			$	4,208
Gross profit		—			1,034		1,937			—				2,971
Direct expenses		11,696			500		3,675			5,341				21,212
Segment contribution		(11,696	)		534		(1,738	)		(5,341	)			(18,241	)
Indirect expenses										2,755		(a)	$	2,755
Loss from operations														(20,996	)
(a) Components of other
Change in fair value of contingent consideration liability										1,725
Amortization										1,030
Total other									$	2,755

	Year Ended December 31, 2020
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net revenues	$	—		$	5,556	$	8,722		$	—			$	14,278
Gross profit		—			3,262		6,084			—				9,346
Direct expenses		51,470			1,653		10,348			20,573				84,043
Segment contribution		(51,470	)		1,609		(4,264	)		(20,573	)			(74,697	)
Indirect expenses										77,228		(a)	$	77,228
Loss from operations														(151,925	)
(a) Components of other
Change in fair value of contingent consideration liability										(55,566	)
Impairment of acquired intangible assets										129,400
Amortization										3,394
Total other									$	77,228

	Year Ended December 31, 2019
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net revenues	$	—		$	5,790	$	15,357		$	—			$	21,147
Gross profit		—			3,815		11,008			—				14,823
Direct expenses		45,789			2,582		17,081			22,390				87,842
Segment contribution		(45,789	)		1,233		(6,073	)		(22,390	)			(73,019	)
Indirect expenses										191,110		(a)	$	191,110
Loss from operations														(264,129	)
(a) Components of other
Change in fair value of contingent consideration liability										68,867
Impairment of acquired intangible assets										118,100
Amortization										4,143
Total other									$	191,110